FDA approves LOPINAVIR AND RITONAVIR from MICRO LABS FDA Approval Dec. 31, 2025, 13:45 UTC 27 0 comments Final approval of ANDA #ANDA #214696 for LOPINAVIR; RITONAVIR. Decision date: 12/11/2025 Comment Full text
FDA regulatory update for UPLIZNA FDA Approval Dec. 31, 2025, 13:45 UTC 29 0 comments Administrative update #SUPPL-4 for VIELA BIO. Status: Approval. Decision date: 12/11/2025 Comment Full text
FDA grants tentative approval for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE from AUROBINDO PHARMA LIMITED FDA Approval Dec. 31, 2025, 13:45 UTC 34 0 comments Tentative approval of ANDA #ANDA #211489 for DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE. Decision date: 12/10/2025 Comment Full text
FDA updates labeling for TRAMADOL HYDROCHLORIDE FDA Approval Dec. 31, 2025, 13:45 UTC 30 0 comments Labeling changes approved for SUN PHARM. Active ingredient: TRAMADOL HYDROCHLORIDE. Decision date: 12/12/2025 Comment Full text
FDA regulatory update for ACTEMRA FDA Approval Dec. 31, 2025, 13:45 UTC 30 0 comments Administrative update #SUPPL-59 for GENENTECH. Status: Approval. Decision date: 12/10/2025 Comment Full text
FDA updates labeling for HYDROCODONE BITARTRATE AND ACETAMINOPHEN FDA Approval Dec. 31, 2025, 13:45 UTC 29 0 comments Labeling changes approved for ACTAVIS LABS FL INC. Active ingredient: ACETAMINOPHEN; HYDROCODONE BITARTRATE. Decision date: 12/11/2025 Comment Full text
FDA updates labeling for DEPO-SUBQ PROVERA 104 FDA Approval Dec. 31, 2025, 13:45 UTC 25 0 comments Labeling changes approved for PFIZER. Active ingredient: MEDROXYPROGESTERONE ACETATE. Decision date: 12/12/2025 Comment Full text
FDA expands indications for AKEEGA FDA Approval Dec. 31, 2025, 13:45 UTC 30 0 comments JANSSEN BIOTECH receives approval for new indications. Submission: SUPPL-1. Decision date: 12/12/2025 Comment Full text
FDA approves LEROCHOL from LIB THERAPEUTICS, INC. FDA Approval Dec. 31, 2025, 13:45 UTC 31 0 comments Final approval of BLA #BLA #761427 for LERODALCIBEP-LIGA. Decision date: 12/12/2025 Comment Full text
FDA updates labeling for XTANDI FDA Approval Dec. 31, 2025, 13:45 UTC 31 0 comments Labeling changes approved for ASTELLAS. Active ingredient: ENZALUTAMIDE. Decision date: 12/11/2025 Comment Full text